EVALUATING HEMORRHAGIC RISK OF ANTITHROMBOTIC THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME
Abstract
Due to prevention and minimization of ischemic complications, antithrombotic therapy with acute coronary syndrome is efficient and justified. However, bleeding as possible adverse effect leaves an open question: where is the boundary between it’s benefit and safety. The bleeding is associated with up to seven times higher mortality during the first month from initiation of the antithrombotic therapy. The level of hemorrhagic risk depends on numerous factors: sex, age, comorbidities, clinical manifestations of acute coronary syndrome, clearance of creatinine, as well as on the therapeutic approach and location of bleeding. The aim of this paper was to point out the significance of evaluation of hemorrhagic risk when initiating and dosing the antithrombotic medication, in order to establish balance between effectiveness and safety and improve prognosis of the disease. Up to now, several scoring systems have been developed to evaluate the risk of bleeding, and their application is recommended on daily basis.
References
Cannon CP, Braunwald E. Unstable Angina and Non-ST Elevation Myocardial Infarction. In Braunwald, Zipes, Libby (Eds): Heart Disease, Textbook of Car-diovascular Medicine 8th ed. W. B. Saunders Com-pany, 2008 Philadelphia, pp. 1319-51
Bassand J, Hamm CW, Ardissino D et al. Guidelines for the diagnosis and treatment of non-ST-segment ele-vation acute coronary syndromes. Eur Heart J 2007; 28(13): 1598-660.
Mackay J, Mensah GA, Mendis S, Greenlund K. The Atlas of Heart Disease and Stroke. Geneva: World Health Organization. 2004.
Incidencija i mortalitet od akutnog koronarnog sindro-ma u 2006, 2007, 2008, 2009. Beograd: Institut za jav-no zdravlje republike Srbije 'Dr Milan Jovanović Batut. [cited 2012 Jul 8]. Preuzeto sa: www.batut.org.rs
Andrade PB, Tebet MA, Maia SFS, Athanazio AMV, Labrunie A, Piva MLAE. Major bleeding in acute coronary syndromes. J Invasive Cardiol 2011; 23(11): 485-90.
Arman TA, Lincoff AM. Antithrombotic Drug The-rapy in Cardiovascular Disease. Humana Press, a part of Springer Science+Business Media, LLC, 2010.
Steen Husted. Benefits and risks with antiplatelet the-rapy: how great a problem is bleeding? European Heart Journal Supplements. 2008; 10 (Supplement I), I19–I24.
Tunstall-Pedoe H. How cardiovascular risk varies with age sex, and coronary risk factors: Do standard risk scores give an accurete perspective. Eur Heart J Suplements 1999;1(suppl D): D25-D31.
Rao SV, Eikelboom JA, Granger CB, Harrington RA, Califf RM, Bassand J. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28(10): 1193-204.
Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KAA, Yusuf S. Adverse impact of bleeding on prog-nosis in patients with acute coronary syndromes. Cir-culation 2006; 114(8): 774-82.
Lopes RD, Alexander KP, Manoukian SV et al. Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009; 53(12): 1021-30.
Kažić T, Ostojić M. (urednici) Klinička kardiovasku-larna farmakologija. 5. izdanje, Integra, Beograd, 2009.
Manoukian SV. Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction. Am J Cardiol 2009; 104: 9-15.
Verheugt FWA, Steinhubl SR, Hamon M, et al. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. J Am Coll Cardiol 2011; 4: 191-7.
Nikolsky E, Stone GW, Kirtane AJ, et al. . Gastrointestinal bleeding in patients with acute coronary syndromes: Incidence, predictors, and clinical implications. J Am Coll Cardiol 2009; 54: 1293-302.
Gaglia MA, Torguson R, Gonzalez MA, et al. Cor-relates and consequences of gastrointestinal bleeding complicating percutaneous coronary intervention.. Am J Cardiol 2010; 106: 1069-74.
Graham I, Atar D, Borch-Johansen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovas Prev Rehabil 2007; 14(suppl 2): 1-113.
Sanchis J, Bodí V, Núñez J et al. New risk score for patients with acute chest pain, non-ST-segment deviation, and normal troponin concentrations: A com-parison with the TIMI risk score. J Am Coll Cardiol 2005; 46(3): 443-9.
Gonçalves PA, Ferreira J, Carlos ACA. TIMI, PUR-SUIT, and GRACE risk scores: Sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J 2005; 26(9): 865-72.
Moscucci M, Fox KAA, Cannon CP et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24(20): 1815-23.
Nikolsky E, Mehran R, Dangas GD et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 2007; 28(16): 1936-45.
Mehran R, Pocock SJ, Nikolsky E et al. A risk score to predict bleeding in patients with acute coronary syn-dromes. J Am Coll Cardiol 2010; 55(23): 2556-66.
Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines. Circulation 2009; 119: 1873-82.
CRUSADE Bleeding Score. www.crusadebleedingscore.org (accessed on 08 September 2012).